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Subfractions in uremic plasma ultrafiltrate inhibit calcitriol metabo-
lism. Previous study from our laboratory has demonstrated that uremic
plasma ultrafiltrate suppresses both the production rate (PR) and
metabolic clearance rate (MCR) of calcitriol in normal rats. To charac-
terize the the substances responsible for the suppression of the synthe-
sis and degradation of calcitriol, we fractionated 20 ml uremie plasma
ultrafiltrates into 13 fractions using high-performance liquid chromatog-
raphy (HPLC) and studied the effect of each fraction n ealcitriol
metabolism. We measured the MCR and PR of calcitriol in normal rats
after they were infused for 20 hours with each fraction dissolved in 20
ml normal saline. Using a UV absorption and fluorescence emission
technique, several known uremic compounds were indentified as indi-
vidual peaks corresponding to the fractions. We found that fractions 4,
and 6 to 13 markedly reduced the MCR of calcitriol. The patterns of the
MCR suppression by the IIPLC fractions suggest that there were at
least two groups of chemically distinguishable compounds. Infusion of
a solution containing all 13 fractions of the uremic ultraliltrate also
inhibited the calcitriol synthesis. One of the 13 fractions (fraction 4,
containing uric acid, xanthine, and hypoxanthine) was further fraction-
ated into eight subfractions. Infusion of subfractions 4 to 7 markedly
reduced both the PR and MCR of calcitriol. We conclude that uremic
plasma ultrafiltrate contains factors that inhibit calcitriol synthesis and
degradation. These substances have molecular weight less than 2,000
Daltons.
Decreased production of calcitriol in renal failure is believed
to be a major factor in the development of the hyperparathy-
roidism, hypocalcemia, and renal osteodystrophy characteristic
of chronic kidney disease [1—31. AItliough loss of renal tissue is
a primary cause of decreased calcitriol production in renal
failure [4], we have shown that ureniic plasma ultrafiltrate
suppresses the production of calcitriol in normal rats [51.
Recent studies from our laboratory have also demonstrated
that the fall in calcitriol production rate (PR) in renal failure is
partially offset by a concomitant decrease in the metabolic
clearance rate (MCR) of calcitriol [4, 51. The observed reduc-
tion in the metabolic clearance of calcitriol appears to minimize
the fall in serum calcitriol concentration in renal failure. While
there may be several reasons for the decreased MCR of
calcitriol in renal failure [6], our initial studies have led to the
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conclusion that uremic substances play a major role in the
suppression of calcitriol metabolism [5, 7].
In this study, we have attempted to characterize the sub-
stances which inhibit calcitriol metabolism, we fractionated
uremic plasma ultrafIltrate into 13 fractions by high perfor-
mance liquid chromatography (HPLC) and studied the effect of
each fraction on calcitriol metabolism. We found two groups of
chemically distinguishable compounds that inhibit metabolic
degradation and synthesis of calcitriol, The substances ap-
peared to have molecular weight less than 2,000 Daltons.
Methods
Normal Sprague-Dawley rats fed with Purina rat chow were
used throughout the study. On the day of experimentation, rats
were weighed and anesthetized with ether. The femoral artery
and vein were cannulated with polyethylene tubing (PE) for
blood sampling and fluid infusion. A PE 50 tube was inserted
into the bladder for urine collection. The animals were placed in
individual cages and allowed to awaken before the experiment.
Uremic plasma ultrafiltrates were obtained from three
chronic hemodialysis patients (three ultrafiltrates from patient
DS, four from VD, and one from TH (ultrafiltrate of this patient
was used only once in a preliminary study). Patients were
dialyzed with 1.3 m2 polysulfone membrane. The ultrafiltrates
were collected at the beginning of dialysis from the effluent side
of the polysulfone membrane. Twenty ml of ultrafiltrate were
aliquoted to 2 ml fractions. Each 2 ml fraction was submitted to
ultrafiltration through an Amicon CentrifreeTM filter (Amicon
Division, WR Grace & Company, Danvers, Massachusetts,
USA). The ultrafiltrate was fractionated with semi-preparative
high-performance liquid chromatography on a RSil C18, 10 s
column (length 25 cm, inner diameter 10 mm) at a flow rate of 3
mI/mm with a linear gradient mobile phase of formic acid (0.05
mol/l, pH 4.0) and methanol. The solvent gradient started with
100% formic acid and 0 to 60% methanol in 45 minutes and 80%
methanol at 52 minutes. Individual peaks were detected by
simultaneous registration of UV-absorption (254 nm) and fluo-
rescence emission (excitation/emission 280/340 nm) in series.
After the ultrafiltrate (10 x 2 ml) was fractionated into 13
fractions, the corresponding fractions were combined and ly-
ophilized [8—111.
To further identify uremic substances eluting as separate
peaks on these chromatograms, the HPLC elution pattern of
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several known uremic solutes was studied. These solutes in- 0.4
cluded creatinine, pseudo-uridine, hypoxanthine, uric acid,
xanthine, p-hydroxyhippuric acid, indoxyl sulfate, hippuric
acid, tryptophan, and indol-3-acetic acid. HPLC was performed
on 3 ml of the mixture of solutes with I ml of water and
processed in a semi-preparative way as above. The same
mixture was also added to 1 ml of uremic ultrafiltrate and
analyzed. In addition, I ml of ultrafiltrate and 3 ml of water 0.2
were mixed, processed and analyzed in the same fashion.
To assess the concentrations of the substances present in
each fraction, the ultrafiltrates were subjected to HPLC analy- 0.1
sis equipped with a light scattering detector. One of the frac-
tions (Fraction 13) with no detectable peaks by either UV
absorption, fluorescence emission or light scattering analysis
was further concentrated 80-fold by stepwise lyophilization and 0.0
then submitted to an analytical HPLC at a flow rate of 0.9
mI/mm (5 sm column, length 25 cm, diameter 4.6 mm).
Each of the 13 HPLC fractions obtained after semi-prepara-
tive fractionation was lyophilized and reconstituted in 20 ml
normal saline. Approximately 0.05 Ci of radiolabelled cal-
citriol was mixed with the 20 ml ultrafiltrate fraction and infused
to a rat for 20 hours. The metabolic clearance of calcitriol
detailed in our previous communications [5—71 was determined
18 and 20 hours after the infusion. Control normal rats (N = 9)
were infused with normal saline. In addition, one normal
plasma ultrafiltrate was obtained by submitting 20 ml of a serum
pool of four healthy donors to centrifugation on an Amicon
CentrifreeTM filter (Danvers, Massachusetts, USA). The ultra-
filtrate was further fractionated in 13 fractions using HPLC and
infused to rats. Two normal rats were infused with saline to
serve as controls.
Fraction 4 (one of the 13 fractions) isolated from 40 ml of
uremic plasma ultrafiltrate was further fractionated into eight
subfractions by HPLC. The solvent gradient started with 100%
formic acid and 0 to 35% methanol in 26 minutes, and 100% in
40 minutes. The subfractions were eluted each minute begin-
ning at 11 minutes till 18 minutes (8 collections). Each fraction
was lyophilized and reconstituted in 20 ml normal saline and
infused to the rats (N = 8). Control rats (N = 4) received 20 ml
normal saline.
Blood samples (0.5 ml) were drawn 18 and 20 hours after the
fluid infusion and the plasma concentrations of radioactive
calcitriol were determined [6, 7]. Our intraassay and interassay
coefficients of variation for radioactive calcitriol were 6.8% and
6,7%. Since there was no difference in the calculated MCR at 18
and 20 hours, only the average values of the MCR were
presented in this study.
At the end of infusion, arterial blood was obtained for the
measurement of blood pH and pCO2 as well as calcitriol,
calcium, phosphorus, and creatinine. Urine was collected dur-
ing the 20-hour infusion for the measurement of calcium,
phosphorus, and creatinine.
The MCR of calcitriol is calculated as:
MCR =
(C)
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The PR of calcitriol is calculated as:
PR = MCR
x endogenous plasma concentration of calcitriol
Analytical methods
Calcium was measured with an atomic absorption spectro-
photometer (Model 306, Perkin Elmer, Norwalk, Connecticut,
USA). Phosphorus and creatinine were measured as described
previously [4, 6]. Blood pH and pCO2 were measured by an IL
713 pH/blood gas analyzer (Instrumentation Lab Inc., Lexing-
ton, Massachusetts, USA). Plasma calcitriol was measured in
duplicate according to the methods of Reinhardt et al [121 and
Hollis [13]. Our interassay coefficients of variation were 7.0%
for low control (20 pg/mI, N = 12) and 4.1% for high control
(100 pg/mI, N = 12). The intraassay coefficients of variation
were 5.4% for low control (N = 6) and 4.7% for high control,
respectively. Calcitriol recovery averaged 65%.
Statistics
All data were expressed as mean SEM. Statistical analysis
was performed using analysis of variance and Student t-test. A
P value of <0.05 was considered significant.
Results
In a preliminary study we have combined all 13 fractions of
one ultrafiltrate each of patient VD and DS and dissolved each
of the combined fractions in 20 ml normal saline. The reconsti-
tuted solutions were infused for 20 hours to two normal rats for
studying their effect on calcitriol metabolism. Two normal rats
received 20 ml normal saline to serve as controls. Plasma
concentrations of calcitriol (saline: 88 pglml, 76 pg/mI, vs.
uremic ultrafiltrate: 62 pg/mI, 66 pg/mI), MCR (saline: 0.34
mI/mm/kg, 0.34 ml/min/kg, vs. 0.16 mI/mm/kg, 0.17 ml/min/kg),
and PR of calcitriol (saline: 43.4 ng/kg/day, 37.3 nglkg/day, vs.
ultrafiltrate: 14.6 ng/kg/day, 15.6 ng/kg/day) were lower in rats
lIfifinfir
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Fig. 1. The metabolic clearance rate (MCR) of rats infused with 13
fractions of uremic plasma ultrafiltrates (N = 5, for each fraction
except fractions 1,2,3, and5 where N = 3) and normal saline (N = 9).
Abbreviation CNT is control rats infused with normal saline.
Infusion rate of 3H-calcitriol
The mean steady state plasma concentration of 3H-calcitriol
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Table 1. Plasma concentration of creatinine, calcium, phosphorus, pH, pCO2 and urinary excretion rate of calcium and phosphorus in rats
infused with saline and fractions of uremic plasma ultrafiltrates
Fraction
no
Body wt
g
Sr
mg/dl
Ccr
rn//mini pCO2 UcaV UpV
/00 g mgidl pH mm Hg g/min
Group 1 (N = 9) 2I2 3.9 0.51 0.01 0.58 0.04 9.68 0.ll 6.95 0.33 7.42 0.01 34.5 0.97 0.26 0.06 18.5 3.0
198 2.l 0.52 0.03 0.64 0,06 9.80 0.19 6.82 0.57 7.42 0.01 34.6 1.5 0.16 0.02 16.4 2.4
199 2.1 0,52 0.02 0.62 0.06 9.64 0.l2 7.25 0.55 7.44 0.01 34.4 0.01 0.22 0.07 15.5 2.9
Group 2 4 202 4.9 0.47 0.02 0.67 0.05 10.08 0.26 6.57 0.50 7.43 0.01 35.5 1.5 0.20 0.03 15.8 1.9
(N =5)
6 204 5,1 0.50 0.02 0.60 0.03 9.62 0.l0 6.10 0.53 7.41 0.01 33.7 1.5 0.18 0.03 14.7 1.9
(N =5)
7
(N =5)
8
(N =5)
9 203 3.1 0.49 0.01 0.62 0.07 9.62 0.12 6.67 4.7 7.42 0.01 35.1 0.90 0.22 0.04 15.5 3.0
(N = 5)
10 207 2.6 0.49 0.02 0.56 0.07 9.88 0.20 7.02 0.57 7.43 0.01 33.6 2.2 0.19 0.08 14.6 3.7
(N =5)
11 210 2.6 0.50 0.02 0.59 0.05 9.80 0.18 6.84 0.53 7.42 0.01 3.30 0.74 0.17 0.03 17.4 2.4
(N =5)
l2 199 2.0 0.52 0.01 0.59 0.03 9.78 0.25 6.34 0.41 7,42 0.01 34.4 1.4 0.12 0.02 15.4 2.5
(N =5)
13 202 5.4 0.51 0.01 0.65 0.07 9.82 0.23 6.63 0.47 7.43 0.01 34.2 1.5 0.27 0.08 16.8 3.2
(N =5)
Abbreviations are: Group 1, Saline infusion; Group 2, Ultrafiltrate infusion; S., plasma creatinine; Car, creatinine clearance; RCa, Plasma
calcium; P1,, plasma phosphorus; U,, and U,V, urinary excretion rate of calcium and phosphorus, respectively. Values are mean SEM
Plasma
Fraction
no. N
calcitriol
pg/rn!
MCR
mi/mm/kg
PR
ngikg/day
Group 1 9 96.9 2.8 0.29 0.01 40.9 2.0
Group 2 4
6
7
8
9
10
II
12
13
5
5
5
5
5
5
S
5
5
94.4 12.1
102.4 7.9
102.4 11.8
113.2 14.1
107.8 16.1
139.1 16.1
111.0 12.1
110.5 6.4
123.6 19.3
0.21 0.OIa
0.24 001b
0.22 0.Ola
0.23 o.oi
0.24 0.0l
0.21 0.0l
0.2I 0.02a
0.21 0.02a
0.19 0.02
29.5 4.6
36.4 3.9
32.3 3.8
36.9 4.5
36.6 5.5
41.1 3.0
33.7 2.8
32.6 2.8
32.8 4.9
Abbreviations are: 2, ultrafiltrate
infused with uremic plasma ultrafiltrates. Further, we have
found that fractions 1, 2, 3 and 5 of patients DS, VD, and TH
d.id not suppress the MCR of calcitriol (Fig. 1), Therefore, only
fractions 4, and 6 through 13 of patients VD and DS were used
in the following experiments.
Infusion of the fractions of uremic plasma ultraflitrates did
not significantly alter the acid-base parameters, plasma concen-
trations of calcium and phosphorus, and urinary excretion rates
of calcium and phosphorus (Table 1).
Table 2 and Figure 1 present the results of calcitriol metab-
olism in rats that received the fractions of uremic plasma
ultrafiltrate. The MCR of calcitriol were significantly lower in
rats infused with fraction 4, and 6 through 13, the plasma
concentrations of calcitriol did not differ from the controls. The
PR of calcitriol tended to decrease by the infusion of these
fractions albeit not significantly. Fractions 4, and 6 through 13
of a normal plasma ultrafiltrate did not appear to suppress the
MCR of calcitriol (fractions 4, 0.26; 6, 0.25; 7, 0.24; 8, 0.24; 9,
0.26; 10, 0.24; 11,0.24; 12, 0.24; and 13, 0.24) when compared
to those of the saline infused rats (N = 2, 0.23 and 0.24).
Animals infused with 40 ml lyophilized subfractions 4 to 7 of
fraction 4 also had lower MCR and PR of calcitriol (Fig. 2). The
mean value of MCR and PR of rats infused with subfractions 4
to 7 were 0.17 0.013 mI/mm/kg and 7.63 3.06 ng/kg/day,
respectively. Both values were significantly lower than the
respective controls (MCR, 0.25 0.012 mI/mm/kg; PR, 27.1
1.10 ng/kg/day, N = 4, both P < 0.001). Subfractions ito 3, and
8 did not affect calcitriol metabolism.
Figure 3 illustrates a typical HPLC elution pattern of an
ultrafiltrate with peak identification by UV absorption and
fluorescence emission. Analysis of a standard solution together
with a mixture of standard solution and uremic ultrafiltrate
identified the individual compounds of the ultrafiltrate (Fig. 3).
This approach allowed us to identify the individual peaks of
creatinine, pseudouridine, uric acid, p-hydroxyhippuric acid,
indoxyl sulfate, hippuric acid, tryptophan, and indol-3-acetic
acid in the uremic fractions. Further, we demonstrated that
fraction 4 contained xanthine, hypoxanthine, and uric acid.
When fraction 4 was subfractionated, uric acid eluted in sub-
fraction 4, hypoxanthine in subfraction 5 to 6, and xanthine in
subfraction 6 to 7, respectively. However, fraction 13, where
the MCR inhibition was maximal, contained no peaks by the
current detection methods.
Light scattering analysis of these 13 fractions further indi-
cated that most of the compounds were present in the left side
of the chromatogram. These compounds eluted in the first 44
Table 2. Metabolic production and clearance of calcitriol in normal
rats infused with saline and HPLC fractions of uremic plasma
ultrafiltrates
Group I, saline infusion; group
infusion, MCR, metabolic clearance rate; PR, production rate.
N = number of rats.
a P < 0.001; b P < 0.01; P < 0.005 compared to saline infusion.
0CD HjiiJ
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Fig. 3. HPLC chromatograms of a standard solution (I, IV) containing
A, creatinine; B, pseudo-uridine; C, uric acid; D, hypoxanthine; E,
xanthine; F, p-hydroxyhippuric acid; G, tryptophan; H, hippuric acid;
I, indoxyl sulfate; J, indol-3 -acetic acid, of uremic ultrafiltrate (II, V),
and of uremic ultrafiltrate with addition of the standard solution (III,
VI). Each of these substances gives rise to a distinct peak. Their elution
zones correspond to the elution zones of existing peaks on HPLC of
uremic ultrafiltrate. Xanthine and hypoxanthine were not identified as
peaks in uremic ultrafiltrate. After addition of the standard to the
ultrafiltrate, the height of the existing peak is increased. Left panel (I,
II, III): UV absorption, right panel (IV, V, VI): fluorescence emission.
minutes (Fig. 4). Using an analytical HPLC, we found the
concentrate (x 80) of fraction 13 had a few small peaks (Fig. 5).
They were, however, not detectable by the conventional meth-
ods.
Fraction
Fig. 4. Elution profile of uremic ultrafiltrate by HPLC and light scat-
tering analysis. The bulk of mass elutes to the left of the chromatogram.
Discussion
The vitamin D endocrine system plays a major role in normal
bone and mineral homeostasis. Calcitriol regulates intestinal
calcium absorption, renal handling of calcium and bone miner-
alization. Although the primary reason for decreased produc-
tion of calcitriol in renal failure is due to loss of normal renal
tissue (4], several studies support the notion that uremic toxins
which accumulate as renal function falls appear to suppress
calcitriol synthesis. We have shown that the calcitriol produc-
tion decreases when normal rats are infused with either phos-
phorus-free urine [7] or uremic plasma ultrafiltrate [5]. Thus,
uremic plasma contains factors that inhibit calcitriol synthesis.
Abnormal calcitriol metabolism in renal failure is not limited
to lower calcitriol synthesis; metabolic clearance of calcitriol is
also reduced in renal failure and uremic substances play a major
role in the suppression of calcitriol degradation [4—7].Although
E
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Fig. 2. The metabolic clearance rate (MCR) and
production rate (PR) of calcitriol of rats infused with
subfractions of fraction 4.
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effects of calcitriol metabolism were limited to subfractions 4 to
7, the findings suggest that compounds with a related structure
were eluted in these regions.
There are at least two groups of chemically distinguishable
compounds in the HPLC fractions responsible for the suppres-
sion of the MCR. The suppression of MCR confined to two
different locations in the elution profiles. One area of inhibition
occurred between the 12th and the 16th elution minute (fraction
4), and the other inhibition spread over wide area after the 20th
elution minute (fractions 6 to 13; Fig. 1). The latter com-
pound(s) possibly released slowly from the HPLC column.
Fraction 4 contained a number of well identified compounds,
for example, uric acid, xanthine, and hypoxanthine (Fig. 3).
These are small water soluble molecules with molecular weights
ranging from 100 to 200 Daltons. In a recent study, we have
found that both the MCR and PR of calcitriol decreased
significantly in rats infused for 20 hours with 20 ml normal saline
containing 50 mgldl of sodium urate. The plasma uric acid
increased from 1.1 mgldl to 4.18 mg/dl and renal li-hydroxylase
activity decreased in these animals after the infusion of urate
[14]. It is noteworthy that the concentration of sodium urate
used in the latter study was conceivably higher than that
observed in the uremic plasma (6 to 13 mgldl) and in the
ultrafiltrate samples employed in the present study (6 to 8
mg/dl). Preliminary studies indicated that fraction 4 also con-
tained guanidinoacetate. However, the effect of guanidinoace-
tate on calcitriol metabolism has not been examined.
A second group of substances suppressing the MCR of
calcitriol was eluted in fractions 6 to 13. The gradual increase in
the suppression of the MCR from fraction 6 to 13 could be due
to a gradual and greater release of the solutes toward the end of
the elution. Light scattering analysis, where extinction is di-
rectly related to the concentration of solutes [15, 161, indicated
that the second half of the HPLC fractions contained a lower
molecular concentration of substances (Fig. 4). Although no
identifiable peaks were observed in fraction 13 with both UV
absorption and fluorescence emission, several individual peaks
were detected by an analytical HPLC in an 80-fold concentrated
sample of this fraction (Fig. 5). This finding suggests that this
fraction contained a substance(s), which possessed a potent
inhibitory effect on MCR at low concentrations.
There were a few major peaks, such as hippuric acid,
indol-3-acetic acid, tryptophan, and indoxyl sulfate (and possi-
bly p-hydroxyhippuric acid) that were recognizable in the
fractions 6 to 13 identified from the elution profiles of the
standard solutions using analytical HPLC technique (Fig. 3)
[10, 111. It is not clear whether any of these compounds perse
could inhibit the MCR. These compounds had their very
distinct elution patterns limited to narrow peak zones. In
contrast, the inhibitory effect of MCR observed in the present
study spread over several elution fractions. Nevertheless, hip-
puric acid, indol-3-acetic acid, tryptophan, and indoxyl sulfate
will be studied for their effects on calcitriol metabolism.
A number of known uremic solutes and toxins, such as
creatinine, pseudo-uridine, methylguanidine, as well as electro-
lytes, phosphate, and glucose are eluted in fractions 1 to 3 and
5. No significant effects of these fractions on the MCR of
calcitriol were found in the present study. Infusion of high
concentration of methylgaunidine also did not change the MCR
of calcitriol [17].
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Fig. 5. Eightyfold concentrated uremic ultrafihtrate (fraction 13) was
subjected to analytical HPLC. Few peaks were identified in the
concentrate (UV absorption, above; fluorescence emission, middle;
light scattering, below).
its significance is not clear, the decreased metabolic clearance
appears to minimize the fall in plasma concentration of calcitriol
in renal failure.
To characterize the substances which alter calcitriol metab-
olism, we fractionated uremic plasma ultrafiltrate into 13 frac-
tions by an HPLC and studied the effect of each fraction on
calcitriol metabolism. The HPLC technique used in this study
excluded inulin (5,200 Da) and parathormone (9424.7 Da).
However, vitamin B12 (1355.4 Da) was eluted and recovered
100% in fraction 8 (unpublished observations). Since the uremic
fractions were processed through the Amicon CentrifreeTM
filter (molecular weight cut-off 30,000 Da) and HPLC over a C18
reversed phase column for separation of low-molecular-weight
compounds (optimum separation for molecular weight limited
to <2,000 Da), we believe that factors inhibiting calcitriol
metabolism were relatively small molecular substances.
Although none of the 13 fractions significantly suppressed
calcitriol synthesis, we have shown that the PR of calcitriol was
lower in rats infused with the combination of all 13 uremic
fractions. Therefore, the absence of the PR suppression in rats
infused with individual fractions could be due to low concen-
trations of the substances in the lyophilized ultrafiltrates. Since
animals infused with fraction 4 appeared to have lower PR and
their plasma calcitriol levels tended to decrease, we studied its
effects on calcitriol synthesis by administering a larger quantity
of the ultrafiltrate. We found that subfractions 4 to 7 of fraction
4 obtained from 40 ml uremic ultrafiltrate markedly inhibited the
production and metabolic clearance of calcitriol. Since the
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